A series of 57 hyperlipidaemic patients have been investigated clinically and by measurement of cholesterol and triglyceride levels and inspection of stored serum. Two had secondary (alcoholic) hyperlipidaemia. Those with primary disorders were allocated to three groups believed to require different optimal therapy. At one year 51 of these 55 patients had lipid levels within a predetermined normal range and two others showed improvement. Despite the large number of primary hyperlipidaemic states our results suggest that in most patients successful treatment can be given according to simple classification into three therapeutic categories.
Introduction
The main rationale for treatment of hyperlipidaemia is the association between abnormally high plasma cholesterol and triglyceride concentrations and ischaemic heart disease (Keys, 1970; Goldstein et al., 1973) . Though the significance of this association has been reinforced by prospective studies showing that raised cholesterol and triglyceride levels are predictive of ischaemic heart disease (Stanler, 1967; Carlson and Bottiger, 1972) rigorous proof is lacking that the association is causal. Nevertheless, it is now common clinical practice to attempt to correct hyperlipidaemia, and this practice obtains further justification from the encouraging results of the "first generation" trials of serum (Christakis et al., 1966; Stamler et al., 1968; Dayton et al., 1969; Miettinen et al., 1972) and of some (Leren, 1970; Dewar, 1971; Oliver, 1971) but not all (Morris, 1968 ) trials of secondary prevention-that is of relapse. Animal experimental evidence that diet-induced hyperlipidaemia leads to atherosclerosis-like lesions has existed for twothirds of a century, and recent suggestions have been made that such lesions are partly reversible by lipidlowering regimens (Armstrong and Megan, 1972 Fredrickson et al. (1967) . This classification into five types, later increased to six, provided valuable clarification of this heterogeneous group of disorders. Recently we have attempted to classify our patients with primary hyperlipidaemia into three therapeutic categories (Lewis, 1973 Underlying causes of hyperlipidaemia were identified in only two patients; this is probably less than the usual frequency of secondary hyperlipidaemia and reflects also the fact that diabetics are not managed at the lipid clinic.
The patients with primary abnormalities of lipid metabolism were divided into the following three groups:
(1) Hypercholesterolaemia (serum cholesterol > 300 mg/ 100 ml, serum triglyceride < 180 mg/100 ml, clear fasting serum). Four patients had tendon xanthomas; 28 patients were allocated to this group.
(2) Endogenous hypertriglyceridaemia (serum triglyceride > 180 mg/100 ml, serum cholesterol < 300 mg/100 ml, diffuse opalescence in stored serum). Eleven patients were allocated to this group.
(3) Hypertriglyceridaemia of exogenous origin (serum triglycerides > 180 mg/100 ml, floating opalescence and clear subnatant in stored serum). No patient's serum had the characteristics of this rare disorder in the present series.
A combination of these characteristics, with raised levels of both cholesterol and triglyceride, occurred in 16 patients.
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In patients with secondary hyperlipidaemia treatment was directed to the underlying cause; in this series there were two patients, both with alcoholic hyperlipidaemia.
Primary Hyperlipidaemia Group 1.-A modified-fat, low cholesterol diet (fat calories 32%, ratio of polyunsaturated to saturated fat 1-4:1, cholesterol 300 mg/day) was prescribed for all patients. In patients with initial serum cholesterol levels exceeding 330 mg/ 100 ml and in those whose cholesterol level was not reduced adequately by diet, treatment with cholestyramine, dextrothyroxine, nicotinic acid, or neomycin was added. Drug therapy was often required. All patients with tendon xanthomas needed a lipid-lowering drug. The most widely used drug was cholestyramine 20-32 g/day. Dextrothyroxine 6-8 mg/day was given to four patients, together with propranolol 20 mg three times daily or practolol 100 mg twice daily (Krikler et al., 1971) to minimize possible thyrocardiac side effects. Criteria for use of dextrothyroxine were freedom from clinical and E.C.G. evidence of ischaemic heart disease and age less than 40 years. In practice it was considered in patients who developed troublesome constipation or dyspepsia as side effects of cholestyramine therapy. Nicotinic acid and neomycin were rarely used, as second-line drugs, for patients who had responded incompletely to diet and cholestyramine.
Group 2.-A reducing diet (600, 800, or 1,000 k/cal) was prescribed for all patients with even mild obesity, aiming to maintain a weight in the middle of the desirable body weight range (Metropolitan Life Insurance Company, 1959) ; a modified-fat, low-cholesterol diet was prescribed in initially lean patients and in patients with hypertriglyceridaemia persisting after weight reduction. Clofibrate 1 g twice daily was prescriibed for the few patients who failed to respond to or were unable to adhere to dietary treatment.
Group 3.-Treatment would comprise low intake of fat containing long-chain fatty acids and partial replacement with medium-chain triglyceride.
Combined Hyperlipidaemia
Patients with combined hyperlipidaemia were treated initially in the same way as those in group 2, except for two who had tendon xanthomas; they were given drug treatment as for group 1.
Results
The relation between the therapeutic groupings and the formal lipoprotein typing based on electrophoresis or ultracentrifugation is shown in table I. Both patients with secondary hyperlipidaemia had the type V lipoprotein pattern due to alcoholism. Neither glycosuria nor fasting hyperglycaemia was observed, possibly due to prior exclusion of diabetics by referring doctors. She was later treated with the addition of clofibrate.
Discussion
Of the 57 patients in this series 51 attained acceptable serum lipid levels and four others showed marked reduction of their 379 hyperlipidaemia. This was achieved using two out of three therapeutic categories, for "pure" hypercholesterolaemia and "pure" endogenous hypertriglyceridaemia; the third category (exogenous hypertriglyceridaemia) was not represented in this series. One-third of the patients had a combination of the first two of these lipid abnormalities. Two features of this approach may be noted. Allocation to the three categories was based on clinical data together with simple laboratory tests. Measurement of cholesterol and triglyceride concentration by manual or automated methods is within the reach of all hospital laboratories, and the qualitative procedure, inspection of stored serum, requires a little experience but is essentially a clinic-room procedure. Secondly, the range of treatments is rationalized; in particular, only three diets are used, compared with six (including the weight-reducing regimens) designed by the National Heart and Lung Institute (1971 (Carlson and Kolmodin-Hedman, 1972) , alphalipoprotein deficiency (Tangier disease) (Lloyd, 1973) , and lecithin: cholesterol acyl-transferase deficiency (Norum et al., 1972) , and an increasing number of secondary hyperlipidaemic states are being recognized.
Though most of our patients responded satisfactorily to treatment the reduction, particularly of raised betalipoprotein levels, was often slow. The rare homozygous form of hvperbetalipoproteinaemia (not seen in the present series) is not always fully corrected even by heroic surgical measures (Moore et al., 1973; Starzl et al., 1973) . There is a need for improved cholesterol-lowering drugs and for better understanding of the indications for the several existing drugs, alone and in combination.
The reasonably satisfactory results obtained in this series partly reflect the type of hyperlipidaemic patien,t referred to a lipid clinic operating in a general hospital. Many presented with complications of atherosclerosis or were asymptomatic relatives of patients with hvperlipidaemia. Most hypercholesterolaemic patients had moderate rather than extreme increases in lipid levels and relatively few had tendon xanthomas. Another factor influencing the success rate was the choice of upper limits of normal. While the predetermined upper limits for cholesterol and triglvceride are in common use it is conceivable that more ambitious targets should be set if the progress of atherosclerosis is to 'be halted.
The results also reflect the generally high degree of dietary adherence by patients, probably related to their frequent initial attendance at the clinic.
A further therapeutic problem, seen in only one of our patients, is that correction of one form of hyperlipoproteinaemia is sometimes followed by increased levels of other lipoproteins. Reduction in betalipoprotein cholesterol level by cholestyramine may be associated with a rise in triglyceride levels due to a high prebetalipoprotein level (Jones and Dobrilovic, 1970) ; and correction of severe hypertriglyceridaemia by clofiibrate may be accompanied by raised betalipoprotein levels (Strisower et al., 1968; Wilson and Lees, 1972). The mechanism of these iatrogenic effects is uncertain. It does not to our knowledge occur when hyperlipidaemia is treated by the modified-fat, low-cholesterol diet, which is in this respect preferable to drug treatment. The 28 men and six women had a mean age of 25 (range 19-39 years). All were Caucasian but of different nationalities -23 Britons, five North Americans, four Australasians, and two South Africans. Patients were all seen initially as outpatients; only those who completed all the necessary investigations of malabsorption were included in the series.
They had had symptoms of diarrhoea for between one and nine months and evidence of malabsorption consistent with the definition of tropical sprue agreed by the Wellcome Trust Collaborative Studies (Mathan and Baker, 1971; Mollin and Booth, 1971; O'Brien and England, 1971 
